Mechanism of Action of Oxytocin
Oxytocin induces labor and controls postpartum hemorrhage by binding to myometrial oxytocin receptors, which stimulates rhythmic uterine contractions that increase in frequency and tone, leading to sustained myometrial contraction that occludes uterine blood vessels at the placental bed. 1
Primary Mechanism in Labor Induction
Oxytocin exerts a selective action on uterine smooth muscle, with response depending on the uterine threshold of excitability. 1 The mechanism operates through several key pathways:
Direct myometrial stimulation: Oxytocin binds to specific oxytocin receptors (OTR) on myometrial cells, stimulating rhythmic contractions and increasing the frequency of existing contractions while raising the tone of the uterine musculature. 1
Receptor sensitivity modulation: High levels of circulating estrogen at term make the oxytocin receptors more sensitive to oxytocin binding, enhancing contractile response. 2
Prostaglandin pathway activation: Oxytocin stimulates prostaglandin synthesis and release in the decidua and chorioamniotic membranes by activating specific oxytocin receptor subtypes, with prostaglandins contributing to both cervical ripening and uterine contractility during labor. 2
Receptor expression dynamics: Myometrial OTR expression is tightly regulated during pregnancy, peaking at labor onset and falling sharply in advanced labor and the postpartum period when the uterus becomes refractory to oxytocin. 3 Control of OTR expression is mediated by steroid hormone stimulation, stretch, and inflammation. 3
Mechanism in Postpartum Hemorrhage Control
The primary physiologic mechanism to stem bleeding from the placental bed after placental separation is not the hemostatic system but sustained myometrial contractions leading to occlusion of uterine blood vessels. 4
Vascular occlusion: Oxytocin enhances uterine contraction and promotes placental separation, with sustained myometrial contraction mechanically compressing and occluding the uterine blood vessels at the placental implantation site. 4, 5
Third stage management: Active management with uterotonics like oxytocin during the third stage of labor reduces bleeding risk by enhancing uterine contractility. 5
Dose-dependent effect: When synthetic oxytocin is administered at infusion rates of 20-30 mIU/min, plasma oxytocin concentration increases approximately 2- to 3-fold above basal levels, producing proportional increases in uterine contractility. 2
Clinical Pharmacology Considerations
Selective uterine action: Synthetic oxytocin does not possess the cardiovascular effects such as elevation of blood pressure exhibited by vasopressin found in posterior pituitary injection. 1
Placental barrier: Synthetic oxytocin administered at recommended dose levels is not likely to cross the placenta or maternal blood-brain barrier. 2
Standard postpartum dosing: 5-10 IU of synthetic oxytocin is routinely given as an intravenous or intramuscular bolus administration after delivery to induce uterine contractility, which induces placental separation and prevents postpartum hemorrhage. 2
Higher dose efficacy: Recent evidence suggests high-dose postpartum oxytocin (80 IU) was associated with lower rates of postpartum hemorrhage compared to lower doses (10-30 IU), with decreased odds of the primary composite outcome (adjusted OR 0.53,95% CI 0.34-0.82). 6
Important Caveats
Uterine hyperstimulation risk: High levels of oxytocin may induce tachystole and uterine overstimulation with potentially negative consequences for the fetus and possibly the mother, requiring careful titration and monitoring. 2, 7
Variable sensitivity: Uterine sensitivity to oxytocin varies between pregnant women, probably reflecting differences in their myometrial OTR expression. 3
Contraindications: Oxytocin should be avoided in cases of cephalopelvic disproportion, and injudicious use to augment weak contractions is a risk factor for uterine rupture. 5